Streptokokkinum (Nosode by Tilch) Simply Explained

1. What It Is About

Streptokokkinum is a nosode. A nosode is a homeopathic remedy made from a pathogen. In the case of Streptokokkinum these are group A streptococci, that is bacteria that can trigger a throat or tonsil infection. The remedy became known through Dr. Andreas Tilch. He uses his own, particularly intensively triturated base substance and unusual dilution levels. According to his description the remedy acts on a state he calls the “Urangst-Modus”: an unconscious feeling of separateness and inner struggle for survival. As applications he names anxieties, traumas passed on over generations and before birth, as well as a tendency to infections. Classically the remedy is used for recurrent streptococcal infections, for example in tonsillitis or pharyngitis. Tilch bases this on his observations from, according to his own statements, over a thousand cases, which he has described in two books.

2. What Studies Show

There is still no study in humans on Streptokokkinum itself. What is known comes from research on related questions. These works show something about the context, not about the remedy itself.

Closest to the topic is a randomised, double-blind pilot study with 62 people with generalised anxiety disorder. Randomised means the allocation to treatment is decided by chance. Double-blind means neither participants nor practitioners know who receives which remedy. All received additional psychological counselling. After three months anxiety in the group receiving the homeopathic remedies had decreased more markedly on the Hamilton Anxiety Scale than under placebo; on the GAD-7 questionnaire no clear difference was seen. No serious adverse events occurred. The authors describe their own work as a pilot study intended to test whether a larger investigation is feasible 3. This study examined homeopathic remedies in anxiety disorders, not Streptokokkinum.

Several reviews classify homeopathy as an adjunctive method. A systematic review of 33 randomised studies in chronic kidney disease lists it alongside Traditional Chinese Medicine and Ayurveda as an investigated procedure 1. Reviews on integrative oncology in France 6 and on complementary procedures in cancer therapy 4 describe it as a low-risk supplement. These works measure homeopathy against specific clinical pictures, not against Streptokokkinum.

A further review addresses the placebo effect, that is improvements arising from expectation, the treatment situation and prior experiences. Such effects are measurable processes in the body. At the same time the authors emphasise that an improvement cannot be attributed to this alone, because the natural course and concomitant treatment also contribute 2.

An open observational study at several centres on the homeopathic remedy Acorus calamus 7 measures a remedy that has so far been little tested against the symptom profiles of the participants. This cannot be transferred to a bacterial nosode preparation.

3. What Remains Unclear

No studies in humans exist on the nosode itself, and the controlled examination is still outstanding. The first open question is what design would allow the described effect to be measured at all.

Independently collected courses are not available: no reports from forums and blogs. The only experiential basis consists of the founder’s case observations. Such observations are experiences and not study results; they say nothing about the share of the natural course, concomitant treatment or expectation in the reported course.

The related works are mixed. In an international randomised study with 344 survivors of critical illness, a targeted intervention against traumatic stress did not change trauma sequelae after six months 5. Duration, adverse events and contradictions cannot be extracted from the data given.

4. What This Means in Everyday Practice

Anyone reading about Streptokokkinum encounters a recent application with one particular feature: so far only the context has been studied, not the remedy. The indications for homeopathic remedies in anxiety and the classification in reviews concern other remedies and other clinical pictures. They are therefore not evidence for Streptokokkinum, but a lead that requires its own examination.

A second point is the treatment situation itself. Expectation, attention and the relationship between practitioner and patient can alter experience. This does not explain every improvement, yet it belongs in every later measurement.

A randomised, double-blind, placebo-controlled study in humans would clarify the question. Participants with recurrent streptococcal infections of the throat or tonsils and with pronounced anxiety symptoms would be appropriate, with anxiety and infections recorded separately. Observation should last at least three months, and evaluation should be independent of manufacturer and practitioner. It remains open whether the overall effect or the contribution of the individual dilution levels should be measured first.

All details with study numbers and sources: detailed page on Streptokokkinum (nosode according to Tilch). For children: Streptokokkinum (nosode according to Tilch) for children.